Search Results for “ diabetes” – Page 52 – media

Boehringer’s new risk-prediction model will tap patients who could be good Jardiance candidates

Boehringer Ingelheim has reason to believe its diabetes medication Jardiance can help fend off cardiovascular death, kidney failure and hospitalization for heart failure. And now, it’s developing a model to help predict which patients are best suited for treatment with the therapy.
- Source: company insights
- 558
- September 28, 2017
cardiovascular Company Insight diabetes kidney
Boehringer collaborates with Gubra to develop next generation obesity treatments

Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
- Source: Biospectrumasia
- 486
- September 14, 2017
cardiometabolic Market Views obesity
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 740
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals
New study examines potential Alzheimer’s disease prevention strategies

The future of researching ways to prevent AD should probably focus on people at risk for developing the disease, said researchers, and should highlight how to improve management of chronic health conditions and education about living healthier.
- Source: news-medical
- 482
- August 10, 2017
Alzheimer's chronic Researches
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 512
- August 4, 2017
Company Insight
Johnson & Johnson Reports 2017 Second-Quarter Results

New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
- Source: www.jnj.com
- 596
- August 4, 2017
Company Insight
EU approves CV benefit claim for Novo’s Victoza

Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
- Source: pharmatimes
- 437
- July 31, 2017
cardiovascular Company Insight diabetes New Approvals
Medical Devices Market in Malysia

Malaysia represents one of the most vigorous and vibrant medical device markets in Southeast Asia, presenting opportunities for U.S. exporters of medical technology to expand their sales into rising economies. Increasing patient access to healthcare will remain in the focus of the Government of Malaysia for the next five years, to include upgrading facilities and equipment, and expanding delivery systems.
- Source: Ddu
- 635
- July 15, 2017
Malaysia Market Reports

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.